Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 8/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | FLT4 | P35916 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427598 | 0.89 | KDR (0.68) | KDRNAMPTFLT1 | |
| SCHEMBL6104350 | 0.85 | KDR (0.57) | KDRHTTFLT1 | |
| SCHEMBL4977683 | 0.83 | KDR (0.71) | KDRHTTNAMPTFLT1ABL1 | |
| SCHEMBL1465969 | 0.80 | WNT3A (0.51) | KDRNAMPTFLT1ABL1EGFR | |
| SCHEMBL1466383 | 0.79 | JAK2 (0.54) | KDRFLT1 | |
| SCHEMBL4940527 | 0.79 | KIT (0.75) | KIT | |
| SCHEMBL4977961 | 0.76 | KDR (0.73) | KDRFLT1ABL1EGFRCSF1R | |
| SCHEMBL426401 | 0.76 | KDR (0.78) | KDRHTTNAMPTFLT1ABL1 | |
| SCHEMBL14007692 | 0.76 | FLT1 (0.49) | KDRHTTNAMPTFLT1 | |
| SCHEMBL5240286 | 0.75 | KDR (0.58) | KDRHTTNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293696-A1 | 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents | ABCC3, HCCS, ABCC2 | KDR 2408/4885HTT 3673/4885NAMPT 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.